Key result
The PEP-CHF trial is designed to evaluate whether perindopril reduces death and unplanned heart failure hospitalizations compared to placebo in 1000 elderly patients with chronic heart failure.
Why the study?
Does perindopril reduce death and unplanned heart failure hospitalizations in elderly patients over 70 with diastolic chronic heart failure?
RCT (n=1,000)
Does perindopril reduce death and unplanned heart failure hospitalizations in elderly patients over 70 with diastolic chronic heart failure?
This paper describes the design of the PEP-CHF study, which aims to evaluate the efficacy of perindopril in elderly patients with diastolic heart failure.
No takes yet. Share an insight, caveat, or question.
Opens needed RCT of perindopril in elderly diastolic HF; leaves open outcome benefit until results reported.
Cleland et al. (1999) conducted an RCT in Chronic heart failure (n=1,000). Perindopril vs. Placebo was evaluated on Death, and unplanned heart failure related hospitalisations. The PEP-CHF trial is designed to evaluate whether perindopril reduces death and unplanned heart failure hospitalizations compared to placebo in 1000 elderly patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: